Craig Heim
Director/Board Member bij Colby Pharmaceutical Co.
Profiel
Mr. Craig Heim is an Assistant Manager-Portfolio at Wisconsin Alumni Research Foundation.
He is on the Board of Directors at Colby Pharmaceutical Co. and Flugen, Inc.
Mr. Heim was previously employed as Vice President by Grace Matthews, Inc.
He received his undergraduate degree from the University of Wisconsin and an MBA from the University of Wisconsin.
Actieve functies van Craig Heim
Bedrijven | Functie | Begin |
---|---|---|
Colby Pharmaceutical Co.
Colby Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Colby is transitioning to a clinical stage drug development company. The company was launched as a Wisconsin Alumni Research Foundation (WARF) spin-out and is strategically aligned with leading clinicians and drug discovery scientists at the University of Wisconsin Paul P. Carbone Comprehensive Cancer Center (UWCCC). Colby is accessing data from funded grants and private investment to develop its therapeutic drugs for therapy-resistant and hypoxic conditions. Colby's lead drugs have unique mechanisms of action and target specific pathways. The company is focused on clinical development of its lead drugs, CPC-100 and -200, in patients with recurrent PCa and other solid tumors, respectively. In 2010, Colby plans to launch a Phase I/IIa study of CPC-100 in men with PCa who fail Androgen Depletion Therapy, as evidenced by rising PSA levels. CPC-200 is being scheduled for a Phase I/IIa in men with high-risk tumors. Colby's two pipeline drugs, CPC-300 and CPC-410 for therapy-resistant metastatic and hypoxic tumors are in late pre-clinical development and are funded by federal grants, including an awarded Colby SBIR grant and by private investors. The Company has demonstrated safety of its lead drugs following efficacy studies in rodents and toxicology studies in mice, rats, and dogs. | Director/Board Member | 17-09-2009 |
Wisconsin Alumni Research Foundation
Wisconsin Alumni Research Foundation Miscellaneous Commercial ServicesCommercial Services Wisconsin Alumni Research Foundation provides research patenting and licensing services. It helps steward the cycle of research, discovery, commercialization, and investment for the University of Wisconsin. The firm provides its support services for the entire cycle of innovation, from research to invention to investment. The company was founded in 1925 and is headquartered in Madison, WI. | Corporate Officer/Principal | 17-09-2009 |
Eerdere bekende functies van Craig Heim
Bedrijven | Functie | Einde |
---|---|---|
FluGen, Inc.
FluGen, Inc. Pharmaceuticals: MajorHealth Technology Flugen, Inc. develops and produces influenza vaccines. Its products include a live attenuated vaccine candidate, a cell-line technology that provides vaccine production efficiency and capacity, and a novel, vaccine-loaded intradermal delivery technology. The company was founded by Yoshihiro Kawaoka, Gabriele Neumann and Paul Radspinner in 2007 and is headquartered in Madison, WI. | Director/Board Member | - |
Grace Matthews, Inc.
Grace Matthews, Inc. Investment ManagersFinance Grace Matthews, Inc. provides merger, acquisition and corporate finance advisory services. Its services include business sales and corporate divestitures, buyouts and leveraged transactions, recapitalizations and acquisitions, and buy-side projects. The company was founded by John L. Beagle and Douglas Mitman in 1999 and is headquartered in Milwaukee, WI. | Corporate Officer/Principal | - |
Opleiding van Craig Heim
University of Wisconsin | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 4 |
---|---|
FluGen, Inc.
FluGen, Inc. Pharmaceuticals: MajorHealth Technology Flugen, Inc. develops and produces influenza vaccines. Its products include a live attenuated vaccine candidate, a cell-line technology that provides vaccine production efficiency and capacity, and a novel, vaccine-loaded intradermal delivery technology. The company was founded by Yoshihiro Kawaoka, Gabriele Neumann and Paul Radspinner in 2007 and is headquartered in Madison, WI. | Health Technology |
Wisconsin Alumni Research Foundation
Wisconsin Alumni Research Foundation Miscellaneous Commercial ServicesCommercial Services Wisconsin Alumni Research Foundation provides research patenting and licensing services. It helps steward the cycle of research, discovery, commercialization, and investment for the University of Wisconsin. The firm provides its support services for the entire cycle of innovation, from research to invention to investment. The company was founded in 1925 and is headquartered in Madison, WI. | Commercial Services |
Grace Matthews, Inc.
Grace Matthews, Inc. Investment ManagersFinance Grace Matthews, Inc. provides merger, acquisition and corporate finance advisory services. Its services include business sales and corporate divestitures, buyouts and leveraged transactions, recapitalizations and acquisitions, and buy-side projects. The company was founded by John L. Beagle and Douglas Mitman in 1999 and is headquartered in Milwaukee, WI. | Finance |
Colby Pharmaceutical Co.
Colby Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Colby is transitioning to a clinical stage drug development company. The company was launched as a Wisconsin Alumni Research Foundation (WARF) spin-out and is strategically aligned with leading clinicians and drug discovery scientists at the University of Wisconsin Paul P. Carbone Comprehensive Cancer Center (UWCCC). Colby is accessing data from funded grants and private investment to develop its therapeutic drugs for therapy-resistant and hypoxic conditions. Colby's lead drugs have unique mechanisms of action and target specific pathways. The company is focused on clinical development of its lead drugs, CPC-100 and -200, in patients with recurrent PCa and other solid tumors, respectively. In 2010, Colby plans to launch a Phase I/IIa study of CPC-100 in men with PCa who fail Androgen Depletion Therapy, as evidenced by rising PSA levels. CPC-200 is being scheduled for a Phase I/IIa in men with high-risk tumors. Colby's two pipeline drugs, CPC-300 and CPC-410 for therapy-resistant metastatic and hypoxic tumors are in late pre-clinical development and are funded by federal grants, including an awarded Colby SBIR grant and by private investors. The Company has demonstrated safety of its lead drugs following efficacy studies in rodents and toxicology studies in mice, rats, and dogs. | Health Technology |